论文部分内容阅读
目的探究对恶性肿瘤患者应用卡培他滨展开治疗过程中引起的手足综合征的发病特点,并对其治疗结果进行观察与分析。方法抽取卡培他滨展开治疗的恶性肿瘤患者263例,观察应用卡培他滨展开治疗过程中引起的手足综合征的发病特点。结果该次研究抽取的263例恶性肿瘤患者中存在手足综合征病例数为154例,占比58.56%。该次研究用药方式涉及3种情形:单独应用卡培他滨、卡培他滨与奥沙利铂联合应用、卡培他滨与多西他赛联合应用,3种情形中存在手足综合征病例数分别为47例(47.96%)、66例(64.08%)、41例(66.13%)。结论对恶性肿瘤患者应用卡培他滨展开治疗过程中,比较常见的并发症为手足综合征。若患者在化疗期间出现手足综合征,应立即给予有效处理措施以降低对患者皮肤的损害程度,同时为了使患者能够顺利实现整个治疗周期的放疗操作,针对卡培他滨应用剂量可以作适当减少处理。
Objective To explore the incidence of hand-foot syndrome caused by capecitabine in patients with malignant tumors and to observe and analyze its treatment results. Methods Totally 263 patients with malignant tumors were treated with capecitabine. The incidence of hand-foot syndrome was observed during capecitabine treatment. Results There were 154 cases of hand-foot syndrome in 263 cases of malignant tumors collected from this study, accounting for 58.56%. The study drug treatment involves three cases: capecitabine alone, capecitabine and oxaliplatin combined use of capecitabine and docetaxel in combination, there are three cases of hand-foot syndrome cases The numbers were 47 (47.96%), 66 (64.08%) and 41 (66.13%) respectively. Conclusions The most common complication of capecitabine in the treatment of cancer patients is hand-foot syndrome. If patients with hand-foot syndrome occur during chemotherapy, they should be given effective treatment immediately to reduce the extent of damage to the skin of patients, and in order to enable patients to successfully achieve the entire treatment cycle of radiotherapy operations, capecitabine dose can be appropriately reduced deal with.